Published in Oncotarget on March 08, 2016
Repeated Long-Term DT Application in the DEREG Mouse Induces a Neutralizing Anti-DT Antibody Response. J Immunol Res (2016) 0.77
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget (2016) 0.76
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 12.00
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Regulatory T cells: key controllers of immunologic self-tolerance. Cell (2000) 10.19
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol (2013) 4.58
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
Regulatory T cells: how do they suppress immune responses? Int Immunol (2009) 3.58
Therapeutic targeting of the tumor microenvironment. Cancer Cell (2005) 2.86
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A (2013) 2.47
Regulatory T cells and cancer. Curr Opin Immunol (2007) 2.41
Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res (2006) 2.37
The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 2.30
Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med (1999) 2.27
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer (2006) 1.91
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One (2006) 1.68
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63
Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest (2006) 1.56
Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen. Proc Natl Acad Sci U S A (2004) 1.27
Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med (2005) 1.26
Mapping of the urinary bladder: its impact on the concepts of bladder cancer. Hum Pathol (1979) 1.14
Regulating the immune response to tumours. Adv Drug Deliv Rev (2006) 1.13
Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas (2003) 1.08
Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study. Urology (2005) 1.07
Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res (2005) 1.06
Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol (2007) 1.04
The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett (2002) 0.96
Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer (1986) 0.96
Detection and significance of TregFoxP3(+) and Th17 cells in peripheral blood of non-small cell lung cancer patients. Arch Med Sci (2014) 0.95
The role of T-cell receptor recognition of peptide:MHC complexes in the formation and activity of Foxp3⁺ regulatory T cells. Immunol Rev (2014) 0.93
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93
The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front Biosci (2008) 0.92
Prognostic value of peripheral and local forkhead box P3(+) regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol (2014) 0.91
Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression. Int J Mol Sci (2014) 0.89
Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother (2011) 0.89
The analysis of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) immunoreactivity within the microenvironment of the ovarian cancer lesion relative to the applied therapeutic strategy. Cell Tissue Res (2011) 0.87
CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One (2014) 0.86
Expression of RCAS1 in esophageal squamous cell carcinoma is associated with a poor prognosis. J Surg Oncol (2005) 0.85
Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report. Am J Reprod Immunol (2011) 0.83
FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol Res (2015) 0.83
Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev (2014) 0.82
Regulatory T cells: how do they find their space in the immunological arena? Semin Cancer Biol (2005) 0.81
Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients. Clin Exp Metastasis (2012) 0.81
Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2014) 0.80
Expression of RCAS1 correlates with urothelial bladder cancer malignancy. Int J Mol Sci (2015) 0.80
Creation of a suppressive microenvironment by macrophages and cancer-associated fibroblasts. Front Biosci (Landmark Ed) (2013) 0.80
Significance of immunoregulatory T cells in different stages of breast cancer patients. Egypt J Immunol (2008) 0.79